Edgewise Therapeutics Inc (EWTX)
17.55
+0.04
(+0.23%)
USD |
NASDAQ |
Jun 17, 11:09
Edgewise Therapeutics Cash from Operations (Quarterly): -28.60M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -28.60M |
| December 31, 2023 | -26.83M |
| September 30, 2023 | -22.06M |
| June 30, 2023 | -20.23M |
| March 31, 2023 | -22.83M |
| December 31, 2022 | -11.86M |
| September 30, 2022 | -11.96M |
| June 30, 2022 | -16.24M |
| March 31, 2022 | -12.57M |
| Date | Value |
|---|---|
| December 31, 2021 | -9.419M |
| September 30, 2021 | -8.262M |
| June 30, 2021 | -9.769M |
| March 31, 2021 | -6.057M |
| December 31, 2020 | -4.638M |
| September 30, 2020 | -3.272M |
| June 30, 2020 | -3.985M |
| March 31, 2020 | -2.739M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-28.60M
Minimum
Mar 2024
-2.739M
Maximum
Mar 2020
-13.02M
Average
-11.86M
Median
Dec 2022
Cash from Operations (Quarterly) Benchmarks
| Pfizer Inc | 1.09B |
| Alnylam Pharmaceuticals Inc | -81.52M |
| Catalyst Pharmaceuticals Inc | 31.92M |
| Cytokinetics Inc | -129.51M |
| Amicus Therapeutics Inc | -29.70M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -268.31M |
| Cash from Financing (Quarterly) | 241.07M |
| Free Cash Flow | -99.39M |
| Free Cash Flow Per Share (Quarterly) | -0.33 |
| Free Cash Flow Yield | -8.11% |